


IN THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is ~~water-soluble~~ a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer and has a molecular weight not greater than 60 kDa.
2. (Cancelled)
3. (Original) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. (Cancelled)
5. (Original) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. (Original) The composition of claim 1, further comprising a targeting ligand.

7. (Currently amended) The composition of claim 1 [[4]], comprising the structure:




wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

8. (Previously presented) A method of treating an angiogenic disease comprising administering a composition of claim 1 to a mammal in need thereof, wherein the

angiogenic disease is a solid tumor, a lymphoma, a leukemia, diabetic retinopathy or macular degeneration.


9. (Cancelled)
10. (Currently amended) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is ~~water-soluble a~~ hydroxypropyl(meth)acrylamide-methacrylic acid copolymer and has a molecular weight not greater than 60 kDa.
11. (Cancelled)
12. (Previously presented) The method of claim 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. (Cancelled)
14. (Original) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.

15. (Original) The method of claim 10, comprising the structure:



wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

16. (Original) The method of claim 15, wherein y is 5-10 and x is 90-95.
17. (Currently amended) An HPMA-TNP-470 conjugate comprising the structure:



Wherein wherein x is 90-95 and y is 5-10.